Floatz logo

(3RS)-1-(6-(.ALPHA.-METHYLPOLY(OXYETHYLENE)AMINO)-6-OXOHEXYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINAMIDE, (20000 MW)

Glioblastoma

Lumicell, Inc.OtherN/ADormant
D
28/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
65/ 100

Competitive context

234 Active assets in the Glioblastoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
Lomustine
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3BB
Enzastaurin
Denovo Biopharma LLC
Phase 3BB
Inno-206
Université de Sherbrooke
Phase 2BB

View all 50 →

Same molecule, other indications

(3RS)-1-(6-(.ALPHA.-METHYLPOLY(OXYETHYLENE)AMINO)-6-OXOHEXYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINAMIDE, (20000 MW) is also rated in:

breast cancerDormant
CCC
Indicative ·
50 / 100
View asset →
Neoadjuvant TherapyDormant
CC
Indicative ·
46 / 100
View asset →
Peritoneal MetastasesDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →